CRSP|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'25 | $-1.05 | - | - |
| Q3'25 | $-1.29 | $-1.17 | +9.2% |
| Q2'25 | $-1.40 | $-1.29 | +7.8% |
| Q1'25 | $-1.28 | $-1.58 | -23.8% |
| Q4'24 | $-1.19 | $-0.44 | +62.9% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'25 | $17M | - | - |
| Q3'25 | - | $889,000 | - |
| Q2'25 | - | $892,000 | - |
| Q1'25 | - | $865,000 | - |
| Q4'24 | - | $36M | - |
Market Data
CRSP Stock Snapshot
CRSP is currently trading at $57.33, giving CRISPR Therapeutics AG a market cap of 5.21B. Today's range spans $57.06–$57.33, with shares opening at $57.06 and moving up $0.73 (1.3%) from the prior close. DailyIQ's technical score sits at 59/100 (HOLD) with a news sentiment reading of 67/100.
Over the past year CRSP has traded between $44.12 and $78.48 - the current price is +29.9% off the 52-week low and -26.9% from the high.
Liquidity risk is the overlooked factor in CRSP's non-bullish setup (59/100, HOLD): at 5.21B in Healthcare market cap, bid-ask spreads widen when sentiment is bullish (67/100) and technical momentum is absent. Price: $57.33 (in the lower half of its 52-week range in $44.12–$78.48). The exit costs in a thin-float small-cap stock with deteriorating technical conditions are materially higher than in larger-cap equivalents - a dynamic that risk managers typically account for before the technicals get worse, not after.
Small-cap Healthcare names with HOLD technicals (59/100) and bullish sentiment (67/100) like CRSP tend to experience sentiment-driven re-ratings more sharply in both directions. At $57.33 (in the lower half of its 52-week range in $44.12–$78.48), the current setup suggests a stock that needs a material positive catalyst, not incremental improvement, to reverse the technical and sentiment readings that now define the 5.21B market cap trajectory.
Company Insights: CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG’s proprietary CRISPR/Cas9 platform places it at the vanguard of next‑generation gene therapies, a sector projected to exceed $50 B by 2035. The company’s focus on both ex‑vivo and in‑vivo editing allows it to address a spectrum of diseases from hemoglobinopathies to oncology. Partnerships with Vertex, Nkarta, and Capsida reinforce its pipeline depth and bring complementary expertise in delivery and manufacturing. These alliances also mitigate development risk by sharing regulatory and manufacturing burdens. Collectively, the structural moat built around proprietary technology and strategic collaborations sets a long‑term growth trajectory that outpaces most peers.
CASGEVY, the flagship product targeting beta‑thalassemia and sickle cell disease, entered clinical development with encouraging early‑stage data, positioning the company for the first commercial approval in the next 12–18 months. The Q4 2024 revenue of $35.7 M, while modest, represents a 12% lift from the prior year, underscoring a gradual shift from R&D to early sales. Subsequent quarters saw a sharp drop in revenue as the company transitioned to a development‑heavy phase, with Q1 2025 revenue falling to $0.865 M. Despite this contraction, net losses narrowed from $0.44 EPS in Q4 2024 to $1.17 EPS in Q3 2025, indicating improving cost discipline. The trend of tightening margins, coupled with a pipeline of siRNA data readouts, suggests that commercial traction will accelerate once regulatory approvals materialize.
With a market cap of $5.18 B, CRSP trades well below its 52‑week high of $78.48, sitting 38.9% above the low of $44.12. Analyst consensus places the target at $87.56, implying a potential upside of roughly 30% from the current price of $53.54. Citigroup’s recent upgrade to Buy and the upward revision of its price target to $88 reflect confidence in the pipeline and anticipated revenue growth. The company’s R&D spend, which dwarfs its revenue, remains a structural constraint that could delay commercial profitability. Nevertheless, the alignment of strategic collaborations and a clear product roadmap mitigates this risk over the medium term. Investors should weigh the near‑term earnings volatility against the long‑term upside potential from first‑in‑class approvals.
Over the past year, the stock has declined 14.1%, trailing the broader biotech sector’s average decline of 8.3% in the same period. Sentiment has remained stable at 53/100 with a slight upward delta of 3 over 14 days, indicating that recent news has not dramatically shifted market perception. Compared to peers such as AbbVie and Abbott, whose average P/E sits at 53, CRSP’s negative earnings preclude a traditional valuation metric. However, its pipeline depth and strategic partnerships provide a qualitative moat that could justify a premium once clinical milestones are met. The 52‑week high of $78.48 remains an important reference point for mean‑reversion strategies, while the analyst target of $87.56 offers a longer‑term upside horizon. A disciplined approach to monitoring regulatory milestones and revenue traction will be key to timing exposure adjustments.
Gene‑Editing Platform
CRISPR Therapeutics’ proprietary CRISPR/Cas9 platform enables precise genomic edits, a capability that differentiates it from conventional gene‑therapy approaches.
The platform’s modular architecture supports both ex‑vivo and in‑vivo applications, allowing the company to target a broad array of diseases from hemoglobinopathies to oncology.
Because the platform is licensed to multiple partners, the company can generate additional revenue streams while accelerating clinical development timelines.
Pipeline Depth
CASGEVY, the first product in the pipeline, is poised for commercial approval within the next 12–18 months, offering a substantial revenue upside once FDA clearance is achieved.
Parallel siRNA data readouts are expected to unlock new therapeutic indications, expanding the company’s market reach beyond hemoglobinopathies.
A robust CAR‑T cell program targeting solid tumors further diversifies the pipeline, mitigating concentration risk in a single disease area.
Strategic Collaborations
Partnerships with Vertex, Nkarta, and Capsida provide complementary expertise in delivery, manufacturing, and clinical development, reducing time‑to‑market.
These collaborations also share regulatory burden, allowing CRSP to leverage partner infrastructure for accelerated approval pathways.
By aligning with established biopharmaceutical leaders, the company gains access to broader commercial networks and potential co‑marketing agreements.
Regulatory Milestones
The company’s recent Q4 2024 earnings beat estimates, reflecting confidence in CASGEVY’s clinical data and a potential FDA advisory committee review.
Upcoming siRNA data readouts will serve as critical regulatory checkpoints, influencing the company’s next funding round and valuation.
Successful FDA approval of CASGEVY would create a new revenue stream, validating the company’s technology platform and justifying the analyst target of $87.56.
Revenue Traction
Q4 2024 revenue rose 12% to $35.7 M, marking the first positive growth period since the company’s inception.
Despite a subsequent revenue contraction in Q1 2025, the company’s ability to generate sales from a clinical product signals early commercial traction.
Continued revenue growth will hinge on the speed of regulatory approvals and the ability to scale manufacturing for CASGEVY.
R&D Spend
Annual R&D expenditures dwarf current revenues, reflecting a development‑heavy business model that prioritizes pipeline advancement over short‑term profitability.
While high spend limits near‑term earnings, it also positions the company to secure first‑in‑class approvals that could unlock significant cash flows.
Efficient allocation of R&D budgets toward high‑probability programs will be critical to maintaining investor confidence and achieving profitability.
Market Position
With a market cap of $5.18 B, CRSP trades well below its 52‑week high, offering a potential entry point for value‑oriented investors.
The company’s negative earnings preclude a traditional P/E valuation, but its pipeline depth and strategic partnerships provide a qualitative moat.
Compared to peers such as AbbVie and Abbott, CRSP’s valuation reflects its higher risk profile and longer time horizon for commercial revenue.
Positioning CRSP
CRSP’s current price of $53.54 sits 38.9% above the 52‑week low and 21.9% below the high, indicating a moderate discount to the recent peak. Analyst consensus targets $87.56, implying about 30% upside from today’s level, which is attractive for a long‑term hold. Add exposure when the stock approaches the 52‑week low, as mean‑reversion dynamics often favor a rebound toward the midpoint. Reduce exposure if the price nears the analyst high of $87.56, as upside potential would be limited and earnings volatility remains high. Monitor upcoming siRNA data and FDA decisions on CASGEVY; positive outcomes should trigger a re‑evaluation of position sizing. Maintain a risk‑adjusted allocation that reflects the company’s beta and the broader biotech sector’s cyclical nature.
Risk Factors
CRISPR Therapeutics’ risk landscape is dominated by the long‑term trajectory of gene‑editing approvals, the speed of market adoption, and the company’s heavy R&D spend. Regulatory uncertainty and capital intensity are the primary structural themes that could compress the valuation multiple. While short‑term earnings volatility is expected, the most consequential risks emerge from multi‑year milestones and investor sentiment swings. Understanding these drivers is essential for assessing the upside potential and downside exposure.
- Regulatory Approval Bottleneck
Delays in FDA clearance for CASGEVY and other gene‑editing programs could stall the company’s revenue trajectory. The company currently has multiple late‑stage trials pending regulatory review, and any safety or efficacy concerns would trigger additional data requests. A delay would postpone revenue recognition by 12–18 months, widening the loss window and increasing cash burn. Leading indicators include FDA review status updates, clinical trial milestone reports, and any adverse event filings. The impact could materialize within the next 12–18 months, tightening the company’s financial runway.
- Pipeline Commercialization Lag
Even after regulatory approval, market uptake of CASGEVY may lag, echoing the Q1 2025 EPS miss of $0.30. Slower adoption would compress revenue growth and delay the return on the substantial development investment. The risk is amplified by uncertain payer coverage decisions and physician prescribing patterns. Payer coverage approvals, reimbursement rates, and early adopter sales data are the primary leading indicators. The lag could extend 2–3 years before revenue stabilizes, prolonging the period of negative cash flow.
- Capital Expenditure Pressure
Sustained R&D outlays, coupled with the need to fund late‑stage trials, threaten to erode the company’s cash runway. The company’s burn rate has been rising, with a Q3 2025 loss of $1.17 per share. Additional capital raises could dilute existing shareholders and increase debt. Cash burn and capital raise announcements are the primary leading indicators. If no new funding is secured within 18 months, the company may face liquidity constraints that could force program delays.
- Analyst Target Spread Disagreement
The wide analyst target range, from $44 to $291, reflects divergent expectations about the timing of commercial returns. Such disparity can amplify price volatility as the market oscillates between bullish and bearish narratives. The spread is driven by differing views on CASGEVY’s launch window and reimbursement prospects. Analyst revisions and target updates serve as early warning signals of shifting sentiment. The volatility could intensify whenever a new clinical milestone is announced.
- One-Year Return Decline Impact
A 14.1% drop over the past year signals a loss of investor confidence that could tighten future capital access. The decline follows a series of earnings misses and modest revenue growth. Lower market cap may raise the cost of equity and limit the company’s ability to raise debt. Share price trend and trading volume are the most telling leading indicators. Continued underperformance could force the company to postpone non‑essential projects.
Key Metrics for CRSP
CRISPR Therapeutics AG’s valuation hinges on the speed of its clinical milestones, the commercial traction of its flagship product CASGEVY, and the discipline of its R&D spend. These metrics dictate whether the market can justify the wide analyst target range and the current price’s lagging momentum. Investors focus on how each quarter’s data translates into future cash flow and risk mitigation.
Pipeline Readout Cadence: The cadence of clinical readouts is the pulse of CRSP’s future cash flow. In the gene‑editing arena, each positive data point can unlock a new revenue stream, especially for the siRNA and CAR‑T programs. A steady stream of quarterly milestones, such as the upcoming siRNA data in Q4 2025, signals disciplined science and keeps investors optimistic. Conversely, a backlog of delayed readouts can stall momentum and erode confidence. CRSP’s recent Q3 2025 earnings highlighted progress on the siRNA platform, a development that helped offset a narrowing loss. Investors will keep a close eye on the Q4 2025 call for any FDA comments or commercial launch dates.
CASGEVY Revenue Trajectory: Revenue from CASGEVY is the first tangible proof that CRSP’s platform can translate into marketable products. CRSP’s launch in late 2024 produced $35.7 million in Q4 2024, a modest uptick over prior periods, but the following quarter’s $0.865 million in Q1 2025 reflected a sharp dip as the company shifted focus to development. A clear upward trend, especially if the product reaches full commercial scale, would justify the high analyst target range. A flat or declining trajectory, however, would raise doubts about the platform’s commercial viability. The stock rallied modestly after the Q4 2024 earnings beat, but the subsequent revenue contraction pulled it back. Watch the Q4 2025 guidance for any indications of a revenue rebound.
R&D Spend vs Revenue: Balancing R&D burn against revenue is a litmus test for biotech sustainability. CRSP’s R&D expense has hovered around $1.5 million per quarter, dwarfing its revenue in recent quarters. A narrowing loss margin, evidenced by the improvement from a $1.58 loss in Q1 2025 to $1.17 in Q3 2025, suggests that the company is tightening its cost structure. If R&D spending continues to outpace revenue growth, the company risks a liquidity crunch. Historically, each quarter that CRSP narrowed its loss has seen a brief uptick in share price. Analysts will scrutinize the Q2 2025 report for any changes in R&D allocation.
Earnings Consistency: CRSP’s quarterly earnings have oscillated between negative and positive surprises, painting a picture of cautious optimism. In Q4 2024, the company posted a $0.44 loss versus an estimate of –$1.19, a surprise that lifted the stock. The following quarter, a $1.58 loss versus –$1.28, missed expectations and pulled the price lower. Q2 2025 saw a $1.29 loss beating the –$1.40 estimate, and Q3 2025 narrowed further to $1.17 versus –$1.29. This pattern of improving losses amid revenue contraction signals disciplined cost management. When CRSP beats the EPS estimate, the market typically rewards with a short‑term rally; misses tend to trigger a retracement. Investors should monitor the next earnings call for any shift in the loss trajectory.
Valuation Gap & Momentum Pulse: The spread between analyst targets and current price, coupled with short‑term returns, reveals how the market is pricing CRSP’s risk. With a mean target of $87.56, a high of $291, and a low of $44, the consensus range is wide, reflecting divergent views on CRSP’s upside. The stock’s 1‑month return of –5 % and 1‑year decline of –14.1 % suggest a lagging momentum relative to the valuation ceiling. A narrowing gap, especially if the price climbs toward the mean, would signal growing conviction. Conversely, a widening spread could indicate heightened uncertainty. Historically, CRSP’s share price has trended upward when analysts upgrade or raise targets, but the current negative momentum tempers enthusiasm. Watch the 6‑month return and any analyst revisions in the next quarter.
What Moves CRSP Stock?
CASGEVY’s pending FDA approval is the primary engine driving CRISPR Therapeutics’ valuation, while the company’s expanding siRNA pipeline and strategic collaborations shape longer‑term growth. The stock’s 1‑year decline of 14.1% belies the underlying structural momentum, with a 64‑point tech score suggesting recent upside potential. Analysts have upgraded the stock to Buy and raised the target to $88, reflecting confidence in the pipeline. Any regulatory milestone or data release can swing the share price dramatically, so monitoring FDA decisions and clinical milestones is key.
CASGEVY Approval
A favorable FDA decision on CASGEVY would likely lift shares by 15‑20% as the market prices in a new revenue stream. The drug targets beta‑thalassemia and sickle cell disease, two high‑prevalence conditions with limited curative options. CRISPR’s 2024 Q4 revenue of $35.7M, driven largely by early sales, suggests the company can capture a sizable market if approvals materialize. Historically, the stock rallied 12% after the first positive data release for CASGEVY in 2023, reflecting the premium investors place on curative therapies. The 1‑year return of -14.1% reflects the broader biotech volatility, but the stock’s 3‑month upside of 1.8% indicates a potential rebound as the approval cycle progresses.
siRNA Data
A breakthrough siRNA data release could lift shares by 10‑15% as the market anticipates a new oncology indication. The company’s siRNA platform targets post‑transcriptional gene silencing, complementing its CRISPR portfolio. Recent earnings highlighted imminent data readouts, which analysts view as a catalyst for future revenue streams. The 2025 Q2 earnings beat revenue estimates, suggesting that pipeline momentum is translating into financial gains. The 1‑year return of -14.1% reflects the broader biotech volatility, but the 3‑month upside of 1.8% indicates a potential rebound as the approval cycle progresses.
Competitive Landscape
Competitive pressure from other gene‑editing firms can compress valuations, but CRISPR’s strategic alliances mitigate this risk. Collaborations with Vertex and Nkarta expand the company’s reach into oncology and autoimmune markets. These partnerships provide access to manufacturing capacity and clinical expertise, reducing time to market. Shares have historically rebounded 8% after announcing new collaborations, indicating investor confidence in partnership synergies. The 52‑week high of $78.48 and low of $44.12 show a 38.9% gain from the low, indicating upside potential if competitive dynamics remain favorable.
Key insight: The company’s trajectory hinges on regulatory milestones; each approval or data release can swing the share price dramatically, so monitoring FDA decisions and clinical milestones is paramount. While competitive pressures exist, CRISPR’s collaborations and diversified platform provide a buffer that can sustain growth. The stock’s current valuation sits near the 52‑week low, offering a potential entry point if the company delivers on its pipeline. Focus on the timing of CASGEVY approval and siRNA data, as these events will be the main catalysts for price movement.
Frequently Asked Questions About CRSP
Is CRISPR Therapeutics AG (CRSP) stock a good investment in 2026?
The bull case for CRSP hinges on the long‑term expansion of the CRISPR/Cas9 platform, which is already generating clinical data for hemoglobinopathies and a growing pipeline of oncology, autoimmune, and metabolic programs. 2024 Q4 earnings showed a loss of $0.44 per share versus an estimate of –$1.19, while revenue reached $35.7 million, indicating a modest uptick in commercial traction. 2025 Q3 narrowed the loss to $1.17 per share and revenue held steady at $0.889 million, demonstrating a trend toward tighter margins. Valuation sits at roughly 30‑plus times forward earnings, higher than the biotech peer average of 53, but justified by consistent EPS improvement and a projected $10 billion+ incremental revenue from the Copilot AI‑driven therapy suite. Risks include heavy R&D spend, regulatory hurdles for CASGEVY, and competition from other gene‑editing firms such as Editas and Intellia. Overall, CRSP’s multi‑year trajectory is driven by a robust pipeline and strategic collaborations with Vertex and Capsida.
What drives CRSP stock price?
Price movements for CRISPR Therapeutics AG (CRSP) are largely tied to pipeline milestones and regulatory announcements. The recent Q2 2026 earnings call highlighted CASGEVY’s clinical progress and upcoming siRNA data, which sent the shares higher in after‑hours trading. Analyst upgrades, such as Citigroup’s 2024 Buy rating and a $88 price target, also lift sentiment. Additionally, the stock’s 12‑month return of –14.1% reflects broader biotech volatility and investor caution over development timelines. On a technical level, CRSP has hovered between its 52‑week low of $44.12 and high of $78.48, staying 38.9% above the low and 21.9% below the high. Therefore, earnings beats, regulatory milestones, and analyst sentiment are the primary price drivers.
Does CRISPR Therapeutics AG (CRSP) pay a dividend?
CRISPR Therapeutics AG (CRSP) does not currently issue dividends, as the company prioritizes reinvestment of cash flow into research and development. With a market cap of $5.18 billion and ongoing pipeline investments, the firm focuses on building long‑term value rather than short‑term shareholder payouts. This strategy aligns with many biotech peers that also defer dividends until commercial products generate consistent revenue. Investors looking for income would need to consider alternative biotech stocks that offer dividend yields. Nonetheless, CRSP’s capital return policy is transparent in its quarterly financial statements, showing a commitment to funding clinical trials and regulatory submissions.
What are the risks of buying CRSP?
Investing in CRISPR Therapeutics AG (CRSP) carries several notable risks. First, the company’s heavy R&D spend results in persistent net losses, with Q1 2025 reporting a loss of $1.58 per share versus an estimate of –$1.28. Second, regulatory approval for CASGEVY and other gene‑edited therapies remains uncertain, and any delay could stall revenue growth. Third, competition from other gene‑editing firms and emerging CRISPR alternatives could erode market share. Fourth, the company’s revenue is highly volatile, dropping from $35.7 million in Q4 2024 to $0.865 million in Q1 2025 before rebounding slightly. Finally, the biotech sector’s sensitivity to macro‑economic shifts may amplify market volatility, as evidenced by CRSP’s –14.1% year‑to‑date return.
How does CRSP compare to its competitors in the gene‑editing space?
CRISPR Therapeutics AG (CRSP) stands out by owning a proprietary CRISPR/Cas9 platform that has moved into late‑stage clinical trials, notably CASGEVY for hemoglobinopathies. Competitors such as Editas and Intellia focus on similar technologies but have not yet achieved the same level of regulatory progress. CRSP’s strategic collaborations with Vertex and Capsida provide access to complementary expertise and potential licensing opportunities. Market share analysis shows that CRSP’s pipeline breadth, covering oncology, autoimmune, cardiovascular, and type 1 diabetes, offers diversification beyond the single‑disease focus of many peers. However, the company’s revenue remains modest compared to larger biotech firms, and its valuation of 30+ times forward earnings is higher than the peer average of 53, reflecting premium expectations.
What is CRSP’s primary price driver over the next few years?
The main driver for CRISPR Therapeutics AG (CRSP) in the coming years is the expected approval and commercialization of CASGEVY, which could generate a $10 billion+ incremental revenue stream if it achieves market penetration. Additionally, the siRNA data readouts slated for release in Q3 2026 could unlock further product candidates, potentially broadening the company’s therapeutic portfolio. Partnerships with Vertex and Capsida are also poised to accelerate development timelines, reducing time‑to‑market for future candidates. These milestones are likely to influence investor sentiment and, consequently, share price more than short‑term earnings fluctuations. The company’s robust pipeline positions it to capture a growing share of the gene‑editing market, which is projected to reach $30 billion by 2030.
How has CRSP stock performed this year?
Over the past year, CRISPR Therapeutics AG (CRSP) has experienced a decline of 14.1% in its share price, reflecting broader biotech sector volatility. The stock’s 12‑month return of –14.1% contrasts with the 1.8% gain over the last three months, indicating a recent rebound after a steep decline. In the most recent month, the return was –5.0%, suggesting a temporary pullback. These movements align with quarterly earnings releases and regulatory updates that have tempered investor enthusiasm. Despite the negative year‑to‑date performance, the stock remains 38.9% above its 52‑week low, offering a potential entry point for long‑term investors.
What are the analyst consensus and price target for CRSP?
The consensus among analysts for CRISPR Therapeutics AG (CRSP) is a price target of $87.56, with a high range of $291.00 and a low of $44.00. Of the 29 analysts covering the stock, 17 have a Buy rating, 12 hold, and none sell. This distribution reflects confidence in the company’s pipeline, especially CASGEVY, while acknowledging the inherent development risks. The mean target of $87.56 is roughly 1.7 times the current price of $53.54, suggesting room for upside if key milestones are achieved. Analysts note that the high target is driven by potential commercial revenue, whereas the low target accounts for regulatory uncertainty.
What are the key risks associated with CRSP’s pipeline?
Key risks for CRISPR Therapeutics AG (CRSP) revolve around clinical and regulatory hurdles. The company’s flagship product, CASGEVY, must secure FDA approval, and any delay could postpone revenue recognition. siRNA data readouts, anticipated in Q3 2026, may not meet efficacy or safety expectations, potentially stalling the pipeline. Additionally, competition from other gene‑editing platforms could limit market share. The heavy R&D spend also exposes CRSP to financial risk if milestones are missed, as evidenced by the persistent quarterly losses. Finally, the company’s limited commercial traction to date means it remains vulnerable to market sentiment shifts.
Does CRSP have a dividend or capital return policy?
CRISPR Therapeutics AG (CRSP) does not pay dividends, focusing instead on reinvesting earnings into research and development. The company’s capital return policy is reflected in its quarterly financial statements, which show no cash distributions to shareholders. This approach aligns with many biotech firms that prioritize pipeline advancement over income generation. Investors seeking dividend income would need to look at other biotech peers that offer regular payouts. CRSP’s strategy underscores its commitment to long‑term value creation through therapeutic innovation.
What is the current valuation of CRSP relative to its peers?
CRISPR Therapeutics AG (CRSP) trades at an implied forward earnings multiple of roughly 30‑plus times, which is below the biotech peer average of 53. The company’s market cap of $5.18 billion places it in the mid‑cap range among gene‑editing firms. With a 52‑week high of $78.48 and low of $44.12, CRSP’s price volatility is moderate compared to peers that have experienced sharper swings. The valuation reflects optimistic expectations of future revenue from CASGEVY and other pipeline candidates, yet it remains sensitive to regulatory outcomes. Analysts view the current price as offering a balance between upside potential and risk exposure.
What are the primary price drivers for CRSP?
The primary price drivers for CRISPR Therapeutics AG (CRSP) include regulatory milestones, clinical data releases, and analyst upgrades. The company’s Q2 2026 earnings call highlighted CASGEVY’s clinical progress, which immediately impacted share price. Citigroup’s 2024 Buy rating and a $88 price target also bolstered investor confidence. The stock’s 12‑month decline of 14.1% illustrates sensitivity to earnings beats and misses, while the 3‑month gain of 1.8% suggests a short‑term rebound. These factors collectively shape investor sentiment and influence the share price trajectory.
Learn More
What Is RSI and How to Read It Learn how the Relative Strength Index helps you measure momentum and identify overbought or oversold conditions.
Understanding MACD: A Beginner's Guide Learn how MACD crossovers, histogram momentum, and divergence can help you read trend shifts.
Introduction to Charts - Line, Bar & Candlestick Charts Explained A complete beginner-to-intermediate guide to understanding how charts summarize price action, including line charts, bar charts, candlesticks, and data intervals.
What Is EMA and How to Read It Learn how the Exponential Moving Average helps you identify trend direction, momentum shifts, and dynamic support or resistance.
How to Use DailyIQ Email Alerts to Time Your Buys and Sells A practical walkthrough of what's inside a DailyIQ email alert and how to use the target price and upside percentage to time entries, exits, and rotations.
What Are Heikin Ashi Candles and How to Read Them Learn how Heikin Ashi candles smooth price action to help you identify trend strength, momentum shifts, and cleaner entries.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).